FBLG
FIBROBIOLOGICS (FBLG)
NASDAQ
$1.05-$0.005 (-0.48%)
Price as of Jun 03, 2026 6:23 PM EDT
  • $6.0M
    Market Cap
  • -93.34%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
N/A
N/A
N/A
N/A
N/A
N/A
Gross Profit
0
N/A
0
N/A
0
N/A
Sales and Marketing Expense
700,000
+21.95%
574,000
N/A
N/A
N/A
Research and Development Expense
-7.4M
+64.45%
-4.5M
+90.20%
-2.4M
N/A
Depreciation and Amortization Expense
244,000
+55.41%
157,000
+234.04%
47,000
N/A
Total Operating Expenses
16.6M
+21.20%
13.7M
+54.54%
8.9M
N/A
Operating Profit
-16.6M
+21.20%
-13.7M
+54.54%
-8.9M
N/A
Interest Income
247,000
-1.59%
251,000
N/A
N/A
N/A
Interest Expense
-204,000
+920.00%
-20,000
-86.39%
-147,000
N/A
Interest Income and Expense and Net
43,000
-81.39%
231,000
+257.14%
-147,000
N/A
Total Nonoperating Income and Expense
-2.0M
-6,340.62%
32,000
+115.02%
-213,000
N/A
Income before Taxes
-16.6M
+49.17%
-11.2M
-41.44%
-19.1M
N/A
Income Taxes
0
N/A
0
N/A
0
N/A
Extraordinary Items
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
-18.6M
+67.06%
-11.2M
-32.30%
-16.5M
N/A
Net Income from Continuing Operations Applicable to Common
-18.6M
+67.06%
-11.2M
-41.44%
-19.1M
N/A
Basic EPS and Net Income
-0.42
+23.53%
-0.34
-50.00%
-0.68
N/A
Diluted EPS and Net Income
-0.42
+23.53%
-0.34
-50.00%
-0.68
N/A
Basic Weighted Average Shares
44.7M
+35.85%
32.9M
+16.45%
28.2M
N/A
Diluted Weighted Average Shares
44.7M
+35.85%
32.9M
+16.45%
28.2M
N/A
Balance Sheet
Cash and Cash Equivalents
4.9M
-65.01%
14.0M
+52.62%
9.2M
N/A
Short-Term Investments
N/A
N/A
N/A
N/A
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
4.9M
-65.01%
14.0M
+52.62%
9.2M
N/A
Total Current Assets
6.3M
-55.38%
14.2M
+54.40%
9.2M
N/A
Accumulated Depreciation
448,000
+119.61%
204,000
+334.04%
47,000
N/A
Property and Plant and Equipment and Net
842,000
+2.18%
824,000
+3.39%
797,000
N/A
Total Long-Term Assets
48,000
-94.17%
824,000
+3.39%
797,000
N/A
Total Assets
9.6M
-41.51%
16.4M
+39.12%
11.8M
N/A
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
0
-100.00%
25.3M
+42,066.67%
60,000
N/A
Total Current Liabilities
1.8M
-86.18%
12.7M
+38.58%
9.2M
N/A
Total Long-Term Debt
N/A
N/A
N/A
N/A
5.6M
N/A
Total Long-Term Liabilities
1.7M
+73.17%
984,000
-28.95%
1.4M
N/A
Total Liabilities
3.5M
-74.74%
13.7M
+29.73%
10.6M
N/A
Retained Earnings
-54.2M
+52.50%
-35.5M
+45.82%
-24.4M
N/A
Total Stockholders Equity
6.2M
N/A
N/A
N/A
1.3M
N/A
Total Shares Outstanding
66.5M
N/A
0
-100.00%
28.2M
N/A
Cash Flow
Cash from Operating Activities
-16.4M
+37.75%
-11.9M
+85.92%
-6.4M
N/A
Capital Expenditures
262,000
+42.39%
184,000
-62.83%
495,000
N/A
Cash from Investing Activities
-262,000
+42.39%
-184,000
-62.83%
-495,000
N/A
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
7.6M
-55.26%
16.9M
+22.58%
13.8M
N/A
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-143.08%
+81.18%
-78.97%
N/A
N/A
N/A
Return on Equity
N/A
N/A
N/A
N/A
N/A
N/A
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
3.61
+222.84%
1.12
N/A
N/A
N/A
Cash Ratio
2.78
+153.19%
1.10
N/A
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow